Effects of Early Physical Therapy and Follow-Up in Acute Severe Coronavirus Disease 2019 Pneumonia: A Retrospective Observational Study

Jaume Bordas-Martínez¹, Ana Luzardo-González², Alejandro Arencibia², Franco Tormo², Lluís Matéu², Vanesa Vicens-Zygmunt¹, Guadalupe Bermudo¹, Salud Santos¹, María Molina-Molina¹*, Rosa Planas² and Guillermo Suarez-Cuartín¹

¹ Respiratory Department, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, University of Barcelona, Barcelona, Spain; ² Rehabilitation Department, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, University of Barcelona, Barcelona, Spain

Background: Rehabilitation in subjects with severe coronavirus disease 2019 (COVID-19) pneumonia has been widely recommended. However, data regarding the starting time of rehabilitation, subjects and healthcare workers’ safety, as well as rehabilitation program features are limited. We aimed to assess the safety and characterize the effect of early and non-early physiotherapy on severe COVID-19 pneumonia subjects.

Methods: A retrospective cohort study, including a consecutive sample of surviving subjects admitted to an acute care hospital due to severe COVID-19 pneumonia from March 13th to May 15th of 2020, is made. Subjects were separated into three groups: non-physical therapy, early physiotherapy (onset <7 days of admission), and non-early physiotherapy. Subject and therapist safety and length of hospital stay were the main evaluated outcomes.

Results: A total of 159 subjects were included (72% men; median age 62 years). Rehabilitation was performed on 108 subjects (32 early and 76 non-early physiotherapies). The length of hospital stay was 19 [interquartile range (IQR) 36.25] and 34 days (IQR 27.25) (p = 0.001) for early and non-early physiotherapy groups, respectively. No physiotherapist was infected and no subject adverse effect was identified. Multivariate analysis of subjects receiving physiotherapy during admission identified obesity [odds ratio (OR) 3.21; p-value 0.028], invasive mechanical ventilation (OR 6.25; p-value <0.001), and non-early physiotherapy (OR 3.54; p-value 0.017) as independent factors associated with a higher risk of prolonged hospital stay. Survivors’ follow-up after hospital discharge at 8 weeks was completed by 54% of subjects.

Conclusion: Rehabilitation in acute severe COVID-19 pneumonia is safe for subjects and healthcare workers and could reduce the length of hospitalization stay, especially in those that may start early.

Keywords: early physical therapy, rehabilitation, pulmonary rehabilitation, COVID-19, SARS-CoV-2
INTRODUCTION

Coronavirus disease 2019 (COVID-19) is produced by the infection of a virus of the coronavirus family [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] identified in December 2019 in China (1). Patients with COVID-19 could develop severe pneumonia in 20% of the cases (2, 3), which is defined by radiographic pneumonia plus respiratory rate >30 breaths-min\(^{-1}\) or severe respiratory distress or oxygen saturation measured by pulse oximetry (\(S\text{O}_2\)) ≤93% on room air at rest (1, 4). Furthermore, 5% of patients with COVID-19 pneumonia may develop multiple organ dysfunction requiring intensive care unit (ICU) admission (2, 3, 5, 6) and life support, including mechanical ventilation, for prolonged periods (2). The most frequent ICU complications related to COVID-19 are acute respiratory distress syndrome (ARDS), in up to 29% of patients (2), and intensive care unit (ICU)-acquired weakness (ICUAW) (7).

Intensive care unit-acquired weakness is a critical illness characterized by polyneuropathy, myopathy, and neuromyopathy that may develop in approximately 40% of patients requiring mechanical ventilation (8–10). In previous coronavirus epidemics, severe acute respiratory syndrome, and middle east respiratory syndrome, around 50% of subjects presented a significant decrease of diffusion capacity, limitation of exercise capacity, and decreased quality of life after several months of hospital discharge (11–14). The first available data related to post-COVID-19 consequences show abnormal pulmonary function and muscle weakness, related to subject functional limitation in their everyday lives (15, 16), especially in elderly patients (17). In this regard, rehabilitation has shown lung function improvement and quality of life recovering in ICU survivors from other diseases (18) and ARDS fatigue (19).

Early rehabilitation has been associated with a reduction of the likelihood of developing ICUAW (20). Initially, rehabilitation in patients with COVID-19 (1, 4) was not performed due to subject and medical staff safety concerns, as there is a possibility of generating airborne aerosols of SARS-CoV-2 particles (21, 22). Undoubtedly, the healthcare work overload and the lack of personal protection equipment at the beginning of the pandemic also played a role (5). However, following the recommendations of main medical societies (23–26) and experts (27–30), early rehabilitation was initiated in stable subjects. Previous data on subacute rehabilitation in COVID-19 have reported promising clinical benefits with no adverse effects reported on either subjects or medical staff (7, 31–34). Nevertheless, studies exploring the early initiation of physical therapy are lacking. Therefore, this study evaluated the impact of rehabilitation on severe COVID-19 pneumonia survivors and compared the potential benefits depending on the time of therapy initiation.

MATERIALS AND METHODS

Study Design

This is a single-center retrospective cohort observational study with prospective follow-up at hospital discharge. The STROBE guidelines (35) for observational studies were followed. Inclusion criteria were: (1) survival of severe COVID-19 pneumonia; (2) requirement of high oxygen support required [inspired oxygen fraction (\(FiO_2\)) >0.5] with high-flow nasal cannula (HFNC), and/or either invasive (IOT-MV) or non-invasive (NIV) mechanical ventilation (MV). All the consecutive patients admitted to the ICU and/or the intermediate respiratory care unit (IMCU) from March 13th until May 15th of 2020 were included. COVID-19 laboratory-diagnostic was performed using nasopharyngeal swab PCR.

According to rehabilitation performance and time of onset, subjects were retrospectively divided into two groups: non-physical therapy and physical therapy, which was further divided into early physiotherapy (defined by therapy start during the first 7 days after admission) and non-early physiotherapy groups. Subjects were followed-up by a pulmonologist with a telephone visit and chest X-ray at 30–60 days of discharge.

This study was approved by the Hospital Ethics Committee (reference code PR168/20). Informed consent of prospective follow-up after hospital discharge was verbally given and appropriately registered in the medical record.

Rehabilitation Program

Rehabilitation was carried out in the ICU and IMCU. The time of therapy initiation was decided according to patient clinical stability (23–25, 36) and the availability of physiotherapists. Not all eligible patients could perform early rehabilitation due to a lack of resources.

The requirements for starting physical therapy were as follows: (1) subject is conscious, oriented, and collaborative; (2) hemodynamically stable without vasoactive support drugs; (3) respiratory rate ≤30 breaths/minute; (4) \(FiO_2\) requirement ≤0.6 for \(SpO_2\) ≥90%; and (5) positive end-expiratory pressure (PEEP) ≤10 cm H\(_2\)O. The rehabilitation session would stop if there was one of the following events: (1) hemodynamic instability; (2) oxygen desaturation lower than 90%; (3) dyspnea higher than 4 points on the Borg scale; and (4) incoercible cough, nausea, or other limiting adverse effects.

Pulmonary and musculoskeletal rehabilitation was performed 5–7 days per week according to physiotherapist availability in ICU and IMCU. Each exercise was repeated between 1 and 10 times depending on patient tolerance with a moderate intensity (never exceeding 4 on dyspnea Borg scale or tachycardia greater than 130 beats per minute). The length of the sessions was 10–15 min. The rehabilitation program involved muscle strength and endurance, inspiratory/expiratory muscle training, guided ventilations, autogenous drainage, and positive expiratory pressure (PEP) exercises. Devices, such as PEP-bottle (37) or Threshold PEP (38), were used when required.

Further information on the rehabilitation program, safety measures, and exercise programs is available in Supplementary Material.

Data Collection

Demographic collected variables were gender, age, and comorbidities, such as hypertension, diabetes mellitus, dyslipidemia, obesity, heart disease, lung disease, kidney
disease, liver disease, and cancer history. Collected clinical data of severe pneumonia were survival time, admission and hospital discharge date, intensive and intermediate critical care requirements with ventilatory and oxygenation support, laboratory serum data [albumin, C-protein reactive (CRP), ferritin, lactate dehydrogenase (LDH), and D-dimer], and pharmacological treatment. The number of physiotherapy sessions, subject adverse events, and physiotherapist COVID-19 contagion were recorded as well. A patient adverse event was considered when the following situations were observed: cardiovascular or respiratory worsening, coughing attacks, or hemodynamic instability. Physical therapist adverse event was considered whether COVID-19 infection was detected or work-related injury was produced due to COVID-19 isolation in ICU or IMCU.

Follow-up was prospectively recorded between 30 and 60 days of hospital discharge including chest X-ray evolution, general status EuroQoL visual analog scale (EQ-VAS) (39), modified medical research council (mMRC) (40) dyspnea scale, and clinical data, such as dry and productive cough, chest pain, palpitations, and neuropathy symptoms.

Statistical Analysis
Statistical analysis was performed using R (software version 3.6.2). Data in the descriptive analysis were presented as frequency (n) and percentage (%) for categorical variables, while as mean and SD or median and interquartile range (IQR) for continuous variables, depending on the normal or non-normal distribution of the variable, respectively. Comparative statistical tests were used for the chi-squared test or Fisher's exact test was used when appropriated. A subgroup analysis was performed only in subjects that underwent physiotherapy during admission to assess the impact of early versus non-early physiotherapy on the length of hospital stay. Prolonged hospitalization was defined as more than 28 days of admission. We performed a multivariate analysis including clinically significant variables. The final model was chosen by Akaike Information Criterion in a stepwise algorithm. A value of \( p < 0.05 \) was considered statistically significant. The STROBE initiative recommendations were used (41).

RESULTS
All the 208 severe COVID-19 subjects who survived the acute phase and were admitted to the ICU or IMCU from March 13th until May 15th of 2020 were included. Of them, 49 who did not require HFNC or MV support were excluded. Of the 159 subjects analyzed, 72% were men and the median age was 61 years old. Hypertension (50%) was the most frequent comorbidity, followed by dyslipidemia (44%), obesity (29%), and diabetes mellitus (27%). Physical therapy was performed in 108 subjects (68%). These subjects were significantly older than those in the non-physiotherapy group (62 vs. 55 years old; \( p \)-value 0.01), and developed a more severe disease with longer ICU admission time, mechanical ventilation, and tracheostomy requirement, as well as worse laboratory profile (low minimum albumin, higher maximum CRP, LDH, and D-dimer blood levels). No physiotherapist was infected by COVID-19 and no adverse effect or worsening in subjects was detected in our study. The non-physical therapy group required significantly less time than the physical therapy group from admission to achieving the sitting position than the physical therapy group (10 vs. 19 days; \( p < 0.001 \)) and to hospital discharge (14 vs. 31 days; \( p < 0.001 \)). Subject characteristics are shown in Table 1.

Among 108 subjects who underwent physical therapy, 32 (30%) started on the first 7 days of admission (early) and 76 (70%) started after the first week of admission (non-early). Their characteristics are depicted in Table 2. Initial admission to the ICU was higher in the early physiotherapy group (56% early vs. 18% non-early; \( p \)-value <0.001), who had shorter time from admission until physical therapy started (4 vs. 13 days, respectively; \( p < 0.001 \)) and sitting position (9.5 vs. 22 days; \( p < 0.001 \)). The length of hospital stay was 19 and 34 days (IQR 36.25 vs. 27.25; \( p = 0.001 \)) in early and non-early physiotherapy groups, respectively.

Multivariate analysis showed that factors independently associated with a higher risk of prolonged hospitalization were obesity [odds ratio (OR) 3.21; 95% CI 1.18–9.66], invasive mechanical ventilation (OR 6.25; 95% CI 2.37–18.33), and starting physiotherapy after the first week of admission (OR 3.54; 95% CI 1.29–10.44) (Table 3).

No significant differences were observed at 60 days follow-up between early and non-early physical therapy groups (Table 4). Oxygen therapy and oral corticosteroid treatment could be reduced at follow-up. Both groups reported dyspnea mMRC 1, neuropathy symptoms, and cough as the most frequent complaints at follow-up.

DISCUSSION
This retrospective study evaluates the features of 108 subjects that started physiotherapy after surviving severe COVID-19 pneumonia and compared the potential benefits depending on the delay in starting this therapy (early versus non-early). The initiation of physical therapy was limited by available resources and safety concerns for subjects and healthcare workers during the first weeks of the pandemic. First and foremost, physical therapy was safe without physiotherapist infection and no adverse effect or worsening in subjects detected. This is consistent with previous rehabilitation studies in critical care units (42), as well as in reported acute (7) and postacute (32, 34, 43–46) COVID-19 rehabilitation studies. Therefore, physical therapy appears to be safe for subjects and healthcare workers.

On the other hand, the benefit of early systemic mobilization in critically ill subjects remains unproven, awaiting longer randomized trials (47), although it is being recommended (17, 28). In this regard, available data on the time of rehabilitation initiation on patients with acute severe COVID-19 pneumonia are still limited (48), with an average of 14 ± 7 days to first mobilization (7). In our study, physiotherapy was initiated within a median of 4 (IQR 2.25) and 13 days (IQR 8.25) from admission.
| TABLE 1 | Subjects characteristics. |
|----------------|----------------------------|
|                | All subjects (n 159) | Non-physiotherapy group (n = 51) | Physiotherapy group (n = 108) | p-value  |
| Age, median (IQR) | 61 (17) | 55 (19) | 62 (15) | 0.010* |
| Male gender, n (%) | 115 (72.33%) | 35 (68.63%) | 80 (74.07%) | 0.598 |
| Hypertension, n (%) | 79 (49.69%) | 20 (45.75%) | 59 (54.63%) | 0.101 |
| Diabetes, n (%) | 43 (27.04%) | 10 (19.61%) | 33 (30.56%) | 0.208 |
| Dyslipidemia, n (%) | 70 (44.03%) | 21 (41.18%) | 49 (45.37%) | 0.744 |
| Obesity, n (%) | 46 (28.93%) | 11 (21.57%) | 35 (32.41%) | 0.223 |
| Cardiopathy, n (%) | 11 (6.92%) | 1 (1.96%) | 10 (9.26%) | 0.175 |
| Chronic respiratory disease, n (%) | | | | |
| -Asthma | 6 (3.77%) | 2 (3.92%) | 4 (3.70%) | 0.849 |
| -COPD | 6 (3.77%) | 3 (5.88%) | 3 (2.78%) | 0.598 |
| -Bronchiectasis | 2 (1.26%) | 0 | 2 (1.85%) | 0.428 |
| -OSA | 8 (5.03%) | 2 (3.92%) | 6 (5.66%) | 0.744 |
| History of malignancies, n (%) | 19 (11.95%) | 7 (13.73%) | 12 (11.11%) | 0.832 |
| Hepatopathy, n (%) | 12 (7.55%) | 5 (9.80%) | 7 (6.48%) | 0.675 |
| Chronic renal disease, n (%) | 8 (5.03%) | 3 (5.88%) | 5 (4.63%) | 0.712 |
| Systemic corticosteroids, n (%) | | | | |
| -IV bolus | 66 (41.51%) | 25 (49.02%) | 41 (37.96%) | 0.029* |
| -IV bolus + oral descending regimen | 43 (27.04%) | 8 (15.69%) | 35 (32.41%) | 0.428 |
| -Oral descending regimen | 6 (3.77%) | 0 | 6 (5.56%) | 0.598 |
| Deep venous thrombosis, n (%) | 12 (7.55%) | 2 (3.92%) | 10 (9.26%) | 0.340 |
| Pulmonary thrombosis, n (%) | 4 (2.52%) | 2 (3.92%) | 2 (1.85%) | 0.594 |
| Subjects situation, n (%) | | | | |
| -Home discharge | 83 (52.20%) | 32 (62.75%) | 51 (47.22%) | 0.135 |
| -Socio-health center discharge | 63 (39.62%) | 17 (33.33%) | 46 (42.59%) | 0.428 |
| -Regional hospital transfer | 13 (8.18%) | 2 (3.92%) | 11 (10.19%) | 0.031* |
| Days from admission to sitting position, median (IQR) | 14.50 (19) | 10 (7) | 19 (23.35) | <0.001* |
| Length of hospital stay in days, median (IQR) | 27 (52.94%) | 27 (52.94%) | 47 (43.52%) | 0.346 |
| Minimum albumin (g/L), mean (SD) | 35.75 (3.97) | 35.94 (4.25) | 35.66 (3.85) | 0.694 |
| Maximum ferritin (µg/L), median (IQR) | 1794 (1635.75) | 1623.80 (1267.25) | 1930 (1892.5) | 0.059 |
| Maximum CRP (mg/L), mean (SD) | 253.30 (131.92) | 201.60 (109.95) | 277.7 (134.82) | <0.001* |
| Maximum LDH (U/L), median (IQR) | 497 (251) | 434 (187) | 537.5 (261.25) | <0.001* |

IQR, Interquartile range; SD, Standard deviation; COPD, Chronic obstructive pulmonary disease; ILD, Interstitial lung disease; OSA, Obstructive sleep apnea; IMCU, Intermediate respiratory care unit; ICU, Intensive care unit; IV, Intravenous; CRP, C-reactive protein; LDH, Lactate dehydrogenase. * Represents significant results with p-value ≤ 0.05.
## Subjects characteristics according to physiotherapy category.

|                           | Early physiotherapy (n = 32) | Non-early physiotherapy (n = 76) | p-value |
|---------------------------|-----------------------------|---------------------------------|---------|
| Age, median (IQR)         | 59.50 (14.25)               | 62.50 (18)                      | 0.009   |
| Male gender, n (%)        | 23 (71.88%)                 | 57 (75%)                        | 0.922   |
| Hypertension, n (%)       | 13 (40.63%)                 | 46 (60.53%)                     | 0.091   |
| Diabetes, n (%)           | 8 (25%)                     | 25 (32.90%)                     | 0.559   |
| Dyslipidemia, n (%)       | 12 (37.50%)                 | 37 (48.68%)                     | 0.393   |
| Obesity, n (%)            | 14 (43.75%)                 | 21 (27.63%)                     | 0.159   |
| Cardiopathy, n (%)        | 4 (12.50%)                  | 6 (7.90%)                       | 0.478   |
| Chronic respiratory disease, n (%) |                |                                 |         |
| -Asthma                   | 1 (3.13%)                   | 3 (3.95%)                       | 0.890   |
| -COPD                     | 0                           | 3 (3.95%)                       |         |
| -Bronchiectasis           | 0                           | 2 (2.63%)                       |         |
| -OSA                      | 2 (6.25%)                   | 4 (5.26%)                       |         |
| History of malignancies, n (%) |                |                                 |         |
| -Immunosuppression, n (%) | 1 (3.13%)                   | 4 (5.26%)                       | > 0.999 |
| Admission ward, n (%)     | 6 (18.75%)                  | 32 (42.11%)                     | < 0.001*|
| -General ward             | 8 (25%)                     | 30 (39.47%)                     |         |
| -IMCU                     | 18 (56.25%)                 | 14 (18.42%)                     |         |
| High-flow oxygen, n (%)   | 25 (78.13%)                 | 40 (51.31%)                     | > 0.999 |
| Non-invasive ventilation, n (%) |              |                                 | > 0.999 |
| Invasive mechanical ventilation, n (%) | 20 (62.50%)    | 46 (60.53%)                     | > 0.999 |
| Tracheostomy, n (%)       | 8 (25%)                     | 22 (29.33%)                     | 0.824   |
| Lopinavir/ritonavir, n (%) | 20 (62.50%)                 | 55 (72.37%)                     | 0.431   |
| Hydroxychloroquine, n (%) | 32 (100%)                   | 75 (98.68%)                     | > 0.999 |
| Interferon beta-1b, n (%) | 11 (34.38%)                 | 26 (34.21%)                     | > 0.999 |
| Tocilizumab, n (%)        | 9 (28.13%)                  | 38 (50%)                        | 0.059   |
| Systemic corticosteroids, n (%) | 13 (40.63%)    | 28 (36.84%)                     | 0.448   |
| -IV bolus                 | 7 (21.88%)                  | 28 (36.84%)                     |         |
| -Oral descending regimen  | 2 (6.25%)                   | 4 (5.26%)                       |         |
| Remdesivir, n (%)         | 6 (18.75%)                  | 6 (7.90%)                       | 0.192   |
| Deep venous thrombosis, n (%) | 1 (3.13%)                | 5 (6.58%)                       | 0.667   |
| Pulmonary thrombosis, n (%) | 1 (3.13%)                | 9 (11.84%)                      | 0.276   |
| Pneumothorax, n (%)       | 0                           | 2 (2.63%)                       | > 0.999 |
| Subjects situation, n (%) | 15 (46.88%)                 | 36 (47.37%)                     | 0.683   |
| -Socio-health center discharge | 15 (46.88%)  | 31 (40.79%)                     |         |
| -Regional hospital transfer | 2 (6.25%)            | 9 (11.84%)                      |         |
| Place of physiotherapy start, n (%) | 23 (71.88%)    | 42 (55.26%)                     | 0.161   |
| -ICU                      | 9 (28.12%)                  | 28 (36.84%)                     |         |
| -IMCU                     | 4 (2.25%)                   | 6 (7.90%)                       | < 0.001*|
| Days from admission to physiotherapy, median (IQR) | 4 (2.25) | 13 (8.25) | < 0.001* |
| Number of physiotherapy sessions, median (IQR) | 20.50 (51.75) | 23 (45) | 0.284 |
| Respiratory secretions, n (%) | 10 (31.25%)     | 30 (39.47%)                     | 0.555   |
| Days from admission to sitting position, median (IQR) | 9.50 (24) | 22 (20) | < 0.001* |
| Length of hospital stay in days, median (IQR) | 19 (36.25) | 34 (27.25) | 0.001* |
| Albumin on admission (g/L), mean (SD) | 32.09 (5.54) | 32.80 (4.99) | 0.179 |
| Minimum albumin (g/L), mean (SD) | 26.06 (5.62) | 25.53 (4.41) | 0.212 |

(Continued)
TABLE 2 | (Continued)

| Early physiotherapy (n = 32) | Non-early physiotherapy (n = 76) | p-value |
|------------------------------|----------------------------------|---------|
| Albumin on discharge (g/L), median (SD) | 34.94 (4.02) | 35.96 (3.77) | 0.953 |
| Maximum ferritin (µg/L), median (IQR) | 1863 (1318.75) | 2100 (2166.25) | 0.288 |
| Maximum CRP (mg/L), mean (SD) | 248.8 (126.09) | 289.80 (137.31) | 0.123 |
| Maximum LDH (U/L), median (IQR) | 452 (180) | 599 (291.50) | <0.001* |
| Maximum D-dimer (µg/L), median (IQR) | 1259.50 (3380.75) | 3283 (4655.25) | 0.021* |

IQR, Interquartile range; SD, Standard deviation; COPD, Chronic obstructive pulmonary disease; ILD, Interstitial lung disease; OSA, Obstructive sleep apnea; IMCU, Intermediate respiratory care unit; ICU, Intensive care unit; IV, Intravenous; CRP, C-reactive protein; LDH, Lactate dehydrogenase. * Represents significant results with p-value ≤ 0.05.

TABLE 3 | The multivariate analysis of prolonged hospitalization (>28 days) of subjects receiving physiotherapy during admission.

|                | Odds ratio | 95% confidence interval | p-value |
|----------------|------------|-------------------------|---------|
| Age ≥70 years  | 2.59       | 0.87–8.55               | 0.099   |
| Obesity        | 3.21       | 1.18–9.66               | 0.288*  |
| Chronic renal disease | 10.56       | 1.30–227.57            | 0.051   |
| Hepatopathy    | 0.15       | 0.01–1.11               | 0.105   |
| Invasive mechanical ventilation | 6.25       | 2.37–18.33             | <0.001* |
| Non-early physiotherapy | 3.54       | 1.29–10.44             | 0.017*  |

* Represents significant results with p-value ≤ 0.05.

TABLE 4 | Subjects characteristics at 60 days from discharge follow-up.

|                | Early physiotherapy (n = 25) | Non-early physiotherapy (n = 61) | p-value |
|----------------|------------------------------|----------------------------------|---------|
| Age, median (IQR) | 57 (101)                   | 62 (17)                         | 0.051   |
| Male gender, n (%) | 19 (76%)                   | 46 (75.41%)                     | >0.999  |
| High-flow oxygen during admission, n (%) | 19 (76%)                   | 47 (77.05%)                     | >0.999  |
| Non-invasive ventilation during admission, n (%) | 14 (56%)                   | 37 (60.66%)                     | 0.875   |
| Invasive mechanical ventilation during admission, n (%) | 13 (52%)                   | 33 (54.10%)                     | >0.999  |
| Tracheostomy during admission, n (%) | 4 (16%)                    | 13 (21.31%)                     | 0.768   |
| Oxygen therapy at discharge, n (%) | 5 (20%)                    | 7 (11.48%)                      | 0.319   |
| Oxygen therapy at follow-up, n (%) | 2 (8%)                     | 3 (4.92%)                       | 0.625   |
| Oral prednisone at discharge, n (%) | 12 (48%)                   | 33 (54.10%)                     | 0.782   |
| Oral prednisone at follow-up, n (%) | 7 (28%)                    | 22 (36.07%)                     | 0.640   |
| Chest X-ray infiltrates at follow-up, n (%) | 14 (63.64%)                | 28 (49.12%)                     | 0.364   |
| Euro QoL, VAS, median (IQR) | 7 (3)                      | 7.50 (2)                        | 0.972   |
| Walking capacity, n (%) | - Completely limited 1 (4%)       | 0                               | 0.074   |
|                       | - Limited to the bedroom 0                      | 0                               |         |
|                       | - Limited to own home 2 (8%)                    | 1 (1.67%)                       |         |
|                       | - No limitations 22 (88%)                        | 60 (98.333%)                    |         |
| Dyspnea mMRC scale at follow-up, median (IQR) | 1 (1)                      | 1 (1)                           | 0.857   |
| Cough, n (%) | 7 (28%)                      | 10 (16.67%)                     | 0.248   |
| Sputum production, n (%) | 2 (8%)                     | 6 (10%)                         | >0.999  |
| Chest pain, n (%) | 3 (12%)                     | 6 (10%)                         | 0.719   |
| Palpitations, n (%) | 1 (4%)                      | 3 (5%)                          | >0.999  |
| Neuropathy, n (%) | 8 (32%)                      | 16 (27.12%)                     | 0.850   |

IQR, Interquartile range; mMRC, Modified Medical Research Committee.

in the early and non-early groups of our severe COVID-19 cohort, respectively.

Interestingly, the time from admission until sitting position and the length of hospitalization were significantly shorter (12.5 and 15 days, respectively) in the early physical therapy group. Mc William et al. (7) identified that obesity and older patients were associated with a delay in time to the first mobilization in patients with acute severe COVID-19. Furthermore, another survivor cohort study of severe COVID-19 pneumonia showed that ventilation requirement was associated with a longer hospital stay (43). Similarly, the analysis of prolonged hospitalization performed in our subjects that underwent physiotherapy
during admission identified that obese subjects, those who required invasive mechanical ventilation, and those who did not initiate early physiotherapy had higher probabilities of prolonged hospital stay.

Recent pulmonary rehabilitation studies in the post-acute phase of COVID-19 pneumonia reported significant benefits in exercise performance, lung function, and reported quality of life (32, 34, 43–46). In our study, follow-up of subject outcomes did not show differences between early and non-early physical therapy groups in terms of dyspnea, walking capacity, reported quality of life, and persistent chest X-ray infiltrates. However, this study lacks a control group without physical therapy to better assess its benefits. Both early and non-early physical therapy groups showed a decrease in oxygen therapy and corticosteroids requirements at 2 months of follow-up. Neuropathy and cough were the most frequently reported symptoms in both groups. Other COVID-19 postdischarge cohorts (49, 50) reported less fatigue, breathlessness, and better-reported quality of life in those subjects without ICU admission.

**Study Limitations**

This study has several limitations and the conclusions have to be taken with caution. First, this is a single-center retrospective non-randomized study, focused only on severe COVID-19 pneumonia. Therefore, the impact of physiotherapy on asymptomatic infection or mild-moderate COVID-19 pneumonia was not evaluated. Second, during the first waves of the pandemic, the lack of knowledge regarding subject and healthcare worker safety, coupled with the lack of resources, conditioned a prioritization of physiotherapy in intensive care units. Consequently, the effect of a systematic and protocolized application of physiotherapy on all subjects cannot be extrapolated. Finally, differences between subjects that received physiotherapy earlier or later could have been influenced by dissimilarities in the severity of the acute phase, such as the previous physical activity of the patient, which were not recorded (17). However, there are few published studies regarding early mobilization in critically ill subjects (47) and even fewer on the acute phase of severe COVID-19 pneumonia (51). Thus, this study has interesting results, such as safety for subjects and healthcare workers. Besides, early physiotherapy could shorten the time until sitting position and length of hospital stay in subjects with more severe illness. In this regard, the results of this study results could be useful to develop prospective well-designed randomized studies in rehabilitation in the acute phase of COVID-19 pneumonia.

**CONCLUSION**

There is no evidence that early or non-early physical therapy could be unsafe for healthcare workers or produce adverse effects in patients with severe COVID-19 pneumonia. Furthermore, physical therapy could reduce the time from admission until sitting position and length of hospital stay.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Hospital Ethics Committee (reference code PR168/20). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

JB-M contributed to literature search, data collection, study design, data analysis, manuscript preparation, and manuscript review. AL-G contributed to data collection, manuscript preparation, and manuscript review. AA, FT, and LM contributed to data collection. VV-Z and SS contributed to study design and manuscript review. GB contributed to data collection and manuscript review. MM-M and GS-C contributed to study design, data analysis, manuscript preparation, and manuscript review. RP contributed to study design, manuscript preparation, and manuscript review. All authors contributed to the article and approved the submitted version.

**FUNDING**

JB-M reports the grant CM20/00093 of Instituto de Salud Carlos III (co-funded by European Social Fund, ESF investing in your future), during the conduct of the study.

**ACKNOWLEDGMENTS**

We thank CERCA Programme/Generalitat de Catalunya for institutional support.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.866055/full#supplementary-material
REFERENCES

1. Wei PF. Diagnosis and Treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl). (2020) 133:1087–95. doi: 10.1097/cmj.0000000000000919

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506.

3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62.

4. World Health Organization. Clinical Management of COVID-19 Interim Guidance. (2020). p. 1–58. Available online at: https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed June 21, 2020).

5. World Health Organization. Coronavirus Disease (COVID-19); Situation Report 145. (2020). Available online at: https://www.who.int/docs/defaultsource/coronaviruse/situationreports/(accessed June 14, 2020).

6. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20.

7. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnasayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. (2013) 310:1591.

8. Hui DSC, Wong KT, Antonio GE, Tong M, Chan DP, Sung JJY. Long-term mortality of adult inpatients with COVID-19. Arch Med Health Sci. (2020) 8:342139. doi: 10.1515/amsr.202005-5606C.

9. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. (2009) 37(SUPPL. 10):S299–308.

10. Appleton RTD, Kinsella J, Quasim T. The incidence of intensive care unit-acquired weakness syndromes: a systematic review. Intensive Care Med. (2015) 16:126–36. doi: 10.1177/174313931563016.

11. Patino M-A, Pichler C, Sonnenberg M, Jeffery P, Falace D, Hall AJ, et al. Rehabilitation levels in patients with COVID-19 admitted to the intensive care unit. Int J Surg. (2020) 25:1–13. doi: 10.1016/j.math.2020.03.011.

12. Bahl P, Doolan C, de Silva C, Chughtai AA, Bourouiba L, MacIntyre CR. Airborne or droplet precautions for health workers treating coronavirus disease 2019? J Infect Dis. (2020) 211:189. doi: 10.1093/infdis/jiaa189 [Epub ahead of print].

13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. (2014) 12:1495–9.

14. Li J, Huang X, Qiu Q, He J, Chen X, Yu B, et al. Clinical Effect of Pulmonary Rehabilitation on Patients with Severe or Critically Severe COVID-19 Pneumonia. (2020). Available online at: https://ssrn.com/abstract=3566145

15. Liu K, Zhang W, Yang Z, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study. Complement Ther Clin Pract. (2020) 39:101166. doi: 10.1016/j.ctcp.2020.10.1166.

16. Pan C, Chen L, Lu C, Zhang W, Xia J-A, Sklar MC, et al. Lung recruiity in COVID-19-associated acute respiratory distress syndrome: a single-center observational study. Am J Respir Crit Care Med. (2020) 201:1294–7. doi: 10.1164/rcrm.202003.0527LE.

17. Zamponga E, Paneroni M, Belli S, Aliani M, Gandolfo A, Visca D, et al. Pulmonary rehabilitation in patients recovering from COVID-19. Respir. Res. (2020) 14:135. doi: 10.1186/s12931-020-01550-2.

18. Liverani B, Nava S, Polastri M. An integrative review on the positive expiratory pressure (PEP)-bottle therapy for patients with pulmonary diseases. Physiother Res Int. (2020) 25:1–13. doi: 10.1002/prj.1823.

19. Demchuk AM, Chatburn RL. Performance characteristics of positive expiratory pressure devices. Respir Care. (2021) 66:482–93. doi: 10.4187/respcare.08150.
39. Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-SD-5L. *Respir Res.* (2018) 19:1–10. doi: 10.1186/s12931-018-0808-x

40. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax.* (1999) 54:581–6. doi: 10.1136/thx.54.7.581

41. Chai K-X, Chen Y-Q, Fan P-L, Yang J, Yuan X. STROBE: the correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis. *Medicine (Baltimore).* (2018) 97:e11775. doi: 10.1097/MD.0000000000011775

42. Nydahl P, Srirachroenchai T, Chandra S, Kundt FS, Huang M, Fischill M, et al. Safety of patient mobilization and rehabilitation in the intensive care unit. Systematic review with meta-analysis. *Ann Am Thorac Soc.* (2017) 14:766–77. doi: 10.1513/AnnalsATS.201611-843SR

43. Herrmann M, Pekacka-Egli A-M, Witassek F, Baumgaertner R, Schoendorf S, Spielmanns M. Feasibility and efficacy of cardiopulmonary rehabilitation after COVID-19. *Am J Phys Med Rehabil.* (2020) 99:865–9. doi: 10.1097/PHM.0000000000001549

44. Curci C, Pisano F, Bonacci E, Camozzi DM, Ceravolo C, Bergonzi R, et al. Early rehabilitation in post-acute COVID-19 patients: data from an Italian COVID-19 rehabilitation unit and proposal of a treatment protocol. *Eur J Phys Rehabil Med.* (2020) 56:633–41.

45. Głowęcki R, Leitl D, Jarosch I, Schweeneger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. *Eur J Open Res.* (2021) 7:00108-2021. doi: 10.1183/23120541.00108-2021

46. Piquet V, Luzczak C, Seiler F, Monar A, Martini A, Ward AB, et al. Do patients with COVID-19 benefit from rehabilitation? Functional outcomes of the first 100 patients in a COVID-19 rehabilitation unit. *Arch Phys Med Rehabil.* (2021) 102:1067–74. doi: 10.1016/j.apmr.2021.01.069

47. Menges D, Seiler B, Tomonaga Y, Schwenklenks M, Puhan MA, Yebyo HG. Systematic early versus late mobilization or standard early mobilization in mechanically ventilated adult ICU patients: systematic review and meta-analysis. *Crit Care.* (2021) 25:16. doi: 10.1186/s13054-020-03446-9

48. Ceravolo MG, De Sire A, Andreelli E, Negrini F, Negrini S. Systematic rapid "living" review on rehabilitation needs due to covid-19: update to march 31st 2020. *Eur J Phys Rehabil Med.* (2020) 56:347–53. doi: 10.23736/S1973-9087.20.06329-7

49. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. *J Med Virol.* (2021) 93:1013–22. doi: 10.1002/jmv.26368

50. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet.* (2021) 397:220–32. doi: 10.1016/s0140-6736(20)32656-8

51. Ceravolo MG, Arienti C, de Sire A, Andreelli E, Negrini F, Lazzarini SG, et al. Rehabilitation and COVID-19: the cochrane rehabilitation 2020 rapid living systematic review. *Eur J Phys Rehabil Med.* (2020) 56:642–51.

**Conflict of Interest**: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note**: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bordas-Martínez, Luzardo-González, Arencibia, Tormo, Matéu, Vicens-Zygmunt, Bermuda, Santos, Molina-Molina, Planas and Suarez-Cuartin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.